{"success":true,"data":{"pressRelease":{"id":"169708","rtpr_id":"nGNX3QgP0j-20261015","ticker":"KURN","exchange":"","all_tickers":["KURN"],"title":"Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026","author":"Globe Newswire","published_at":"2026-10-15T05:00:00.370Z","article_body":"Ad hoc announcement pursuant to Article 53 of the SIX listing rules\n\nKuros Biosciences increases 2026 annual guidance\nThe company reports 40% year-over-year increase in sales in the first nine\nmonths of 2026\n\nSchlieren (Zurich), Switzerland, October 15, 2026 – Kuros Biosciences\n(“Kuros” or the “Company”) a leader in next generation bone healing\ntechnologies, today announced its financial performance for the first nine\nmonths of 2026.\n\nFinancial Highlights\n* Total Medical Device sales increased 40% to USD 141.8 million (9M 2025: USD\n101.1 million)\n* Total Group EBITDA increased 81% to USD 13.5 million (9M 2025: USD 7.4\nmillion)\n* The Group adjusted EBITDA* increased 68% to USD 20.6 million, equaling a\nmargin of 14.5% (9M 2025: USD 12.2 million or 12.1%)\n* Cash position ahead of plan at USD 19.6 million, up from USD 9.7 million as\nof June 30, 2026\nOperational & Clinical Highlights\n* Made in the U.S. and the Netherlands – Kuros’ new Alpharetta, Georgia\nfacility began commercial production of MagnetOs bone graft in October 2026.\nTogether with its Bilthoven, Netherlands site, this gives Kuros dual-site\nmanufacturing, including production in its largest market, to support capacity\nand supply-chain resilience\n* Level I trials pass key thresholds – PROOF reached 97% enrollment and\nPRECISE surpassed its halfway mark at 55%, advancing both posterolateral\nfusion studies. ASTRA advanced to 18% in hindfoot and ankle fusion, extending\nprospective evidence across spine and extremities\nOutlook\n* Reflecting the continued strength of the business, the Group raises its\nfull-year guidance and now expects sales growth of 36% to 40% and an adjusted\nEBITDA margin of more than 14.5%\nChris Fair, Chief Executive Officer of Kuros Biosciences, said “Our strong\nperformance through the first nine months of 2026 reflects continued revenue\ngrowth, record adjusted EBITDA, increasing profitability and a cash position\nahead of plan. I am particularly proud that we have activated our second\nproduction facility in Alpharetta, Georgia, on time and on budget. We are\nencouraged with the pace of enrollment in our three prospective Level I\nclinical trials across spine and extremities. We are pleased to raise our\nfull-year 2026 guidance for revenue growth and adjusted EBITDA, even after\nthese substantial investments.”\n\nFor further information, please contact:\n\n Alexandre Müller      Daniel Geiger               \n Investor Relations    Chief Financial Officer     \n Tel +41 43 268 32 31  Tel +41 44 733 47 41        \n IR@kurosbio.com       daniel.geiger@kurosbio.com  \n\n        \n\nAbout MagnetOs\nGrowing bone with MagnetOs(TM) gives surgeons confidence where it matters most\n– delivering predictable fusion outcomes.(1) In a Level I human clinical\nstudy published in Spine, MagnetOs achieved nearly twice the fusion rate of\nautograft (79% vs. 47%) in posterolateral fusions (PLFs).(1) Among active\nsmokers – who made up 1 in 5 patients – the fusion difference between\nMagnetOs and autograft was even more dramatic.(*)(*)(1)(,2) MagnetOs grows\nbone on its own thanks to NeedleGrip(TM) – a proprietary submicron surface\ntechnology that harnesses the immune system to stimulate bone growth, without\nadded cells or growth factors.(†)(3-5) Ready-to-use, easy to mold, and\nreliably staying put, MagnetOs carries no intrinsic risk of human\ntissue-related disease transmission and is FDA cleared for use throughout the\nspine, including interbody procedures.(‡6-11) Additionally, MagnetOs\nGranules, MagnetOs Putty, MagnetOs Easypack Putty and MagnetOs MIS are also\ncleared for use in the extremities and pelvis.(7-10)\n\nIndications Statement\nPlease refer to the instructions for use for your local region for a full list\nof indications, contraindications, warnings, and precautions.\n\nAbout Kuros Biosciences\nKuros Biosciences is on a mission to discover, develop, and deliver innovative\nbiologic technologies. With locations in the U.S., Switzerland, and the\nNetherlands, the company is listed on the SIX Swiss Exchange. The company’s\nfirst commercial product, MagnetOs(TM), is a unique advanced bone graft that\nhas already been used across five continents. For more information on the\ncompany, its products, and pipeline, visit kurosbio.com\n(https://www.globenewswire.com/Tracker?data=SSCyR1CiAjyhLcNmuQpJHJJs6w8H78BVzAE69ZuSAHvI3zfnsMKrMOmqsadGEyN6jKIivnrCULFuqBa6mMyKmmQAwGhdOQV7WhKjI8fYeruy-jTJZyqGvHavkpzjjX4NxzN_9eHAogDGmM2EEh52TzHmioBhbvcq1PnCyhcTEM7Qk9xbJY1naPc6GJ9XO8wj0O8lCC0Oy9hILGlks473CdRjrljrHsWPb6psyQxVaeHz0on9T6e29mDnDHcdyyveWa4dYOFcF6aWC7gZCp6UKyMabLarpKXhQMiKP3LXgzILqFVYpHE1T_RmxbVaJ_kPrI_XhmvuPZFFAwBvtJ3X3boW_roLB4ZsgGssOZGz1bXO85Lvgfz7Tpt9PAk28iiz).\n\nForward Looking Statements\nThis media release contains certain forward-looking statements that involve\nrisks and uncertainties that could cause actual results to be materially\ndifferent from historical results or from any future results expressed or\nimplied by such forward-looking statements. You are urged to consider\nstatements that include the words “will” or “expect” or the negative\nof those words or other similar words to be uncertain and forward-looking.\nFactors that may cause actual results to differ materially from any future\nresults expressed or implied by any forward-looking statements include\nscientific, business, economic, and financial factors. Against the background\nof these uncertainties, readers should not rely on forward-looking statements.\nThe Company assumes no responsibility for updating forward-looking statements\nor adapting them to future events or developments.\n\n*Adjusted EBITDA excludes research and development costs incurred to complete\nphase 2a of Fibrin-PTH (KUR-113) (discontinued operation), recurring and\none-time share-based compensation, the related social security charges, and\ntemporary tariff-related cost. Management believes this supplemental measures\nprovides useful information to investors by presenting the underlying\noperating performance of the business before the impact of import duties. **19\nof initial 100 patients were active smokers. Radiographic fusion data of the\nsmoker subgroup were not statistically analyzed as a subgroup and were not\nincluded in the peer-reviewed publication of the study.(1) †Results from in\nvivo or in vitro laboratory testing may not be predictive of clinical\nexperience in humans. Please refer to the Instructions for Use for a full list\nof indications, contraindications, precautions, and warnings. MagnetOs is not\ncleared by the FDA or TGA as an osteoinductive bone graft. ‡MagnetOs must\nalso be used with an intervertebral body fusion device cleared by FDA for use\nwith a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA and\nmixed with autograft in posterolateral spine and intervertebral disc space.\nMagnetOs Granules must be hydrated with blood in the intervertebral disc\nspace.\n\n1. Stempels, et al. Spine. 2024;49(19):1323-1331. 2. Van Dijk, LA. 24th SGS\nAnnual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug\n2024. 3. Van Dijk, et al. eCM. 2021;41:756-73. 4. Van Dijk, et al. J Immunol\nRegen Med. 2023;19:100070. 5. Duan, et al. eCM. 2019;37:60-73. 6. Data on\nfile. MagnetOs Putty and MagnetOs Easypack Putty. 7. Instructions for Use\n(IFU) MagnetOs Granules (US). 8. Instructions for Use (IFU) MagnetOs Putty\n(US). 9. Instructions for Use (IFU) MagnetOs Easypack Putty (US). 10.\nInstructions for Use (IFU) MagnetOs MIS (US). 11. Instructions for Use (IFU)\nMagnetOs Flex Matrix (US).\n\nAttachment\n*     Kuros Biosciences Press Release Q3 2026 Results 10-15-26\n(https://ml-eu.globenewswire.com/Resource/Download/a250cd45-25ac-409d-935f-1c858cce8a8b)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ad3777c9-af1f-4b09-a899-3b3d6b8e962d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3QgP0j-20261015","title":"Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026","author":"Globe Newswire","ticker":"KURN","created":"2026-10-15T05:00:00.370Z","tickers":["KURN"],"exchange":"","article_body":"Ad hoc announcement pursuant to Article 53 of the SIX listing rules\n\nKuros Biosciences increases 2026 annual guidance\nThe company reports 40% year-over-year increase in sales in the first nine\nmonths of 2026\n\nSchlieren (Zurich), Switzerland, October 15, 2026 – Kuros Biosciences\n(“Kuros” or the “Company”) a leader in next generation bone healing\ntechnologies, today announced its financial performance for the first nine\nmonths of 2026.\n\nFinancial Highlights\n* Total Medical Device sales increased 40% to USD 141.8 million (9M 2025: USD\n101.1 million)\n* Total Group EBITDA increased 81% to USD 13.5 million (9M 2025: USD 7.4\nmillion)\n* The Group adjusted EBITDA* increased 68% to USD 20.6 million, equaling a\nmargin of 14.5% (9M 2025: USD 12.2 million or 12.1%)\n* Cash position ahead of plan at USD 19.6 million, up from USD 9.7 million as\nof June 30, 2026\nOperational & Clinical Highlights\n* Made in the U.S. and the Netherlands – Kuros’ new Alpharetta, Georgia\nfacility began commercial production of MagnetOs bone graft in October 2026.\nTogether with its Bilthoven, Netherlands site, this gives Kuros dual-site\nmanufacturing, including production in its largest market, to support capacity\nand supply-chain resilience\n* Level I trials pass key thresholds – PROOF reached 97% enrollment and\nPRECISE surpassed its halfway mark at 55%, advancing both posterolateral\nfusion studies. ASTRA advanced to 18% in hindfoot and ankle fusion, extending\nprospective evidence across spine and extremities\nOutlook\n* Reflecting the continued strength of the business, the Group raises its\nfull-year guidance and now expects sales growth of 36% to 40% and an adjusted\nEBITDA margin of more than 14.5%\nChris Fair, Chief Executive Officer of Kuros Biosciences, said “Our strong\nperformance through the first nine months of 2026 reflects continued revenue\ngrowth, record adjusted EBITDA, increasing profitability and a cash position\nahead of plan. I am particularly proud that we have activated our second\nproduction facility in Alpharetta, Georgia, on time and on budget. We are\nencouraged with the pace of enrollment in our three prospective Level I\nclinical trials across spine and extremities. We are pleased to raise our\nfull-year 2026 guidance for revenue growth and adjusted EBITDA, even after\nthese substantial investments.”\n\nFor further information, please contact:\n\n Alexandre Müller      Daniel Geiger               \n Investor Relations    Chief Financial Officer     \n Tel +41 43 268 32 31  Tel +41 44 733 47 41        \n IR@kurosbio.com       daniel.geiger@kurosbio.com  \n\n        \n\nAbout MagnetOs\nGrowing bone with MagnetOs(TM) gives surgeons confidence where it matters most\n– delivering predictable fusion outcomes.(1) In a Level I human clinical\nstudy published in Spine, MagnetOs achieved nearly twice the fusion rate of\nautograft (79% vs. 47%) in posterolateral fusions (PLFs).(1) Among active\nsmokers – who made up 1 in 5 patients – the fusion difference between\nMagnetOs and autograft was even more dramatic.(*)(*)(1)(,2) MagnetOs grows\nbone on its own thanks to NeedleGrip(TM) – a proprietary submicron surface\ntechnology that harnesses the immune system to stimulate bone growth, without\nadded cells or growth factors.(†)(3-5) Ready-to-use, easy to mold, and\nreliably staying put, MagnetOs carries no intrinsic risk of human\ntissue-related disease transmission and is FDA cleared for use throughout the\nspine, including interbody procedures.(‡6-11) Additionally, MagnetOs\nGranules, MagnetOs Putty, MagnetOs Easypack Putty and MagnetOs MIS are also\ncleared for use in the extremities and pelvis.(7-10)\n\nIndications Statement\nPlease refer to the instructions for use for your local region for a full list\nof indications, contraindications, warnings, and precautions.\n\nAbout Kuros Biosciences\nKuros Biosciences is on a mission to discover, develop, and deliver innovative\nbiologic technologies. With locations in the U.S., Switzerland, and the\nNetherlands, the company is listed on the SIX Swiss Exchange. The company’s\nfirst commercial product, MagnetOs(TM), is a unique advanced bone graft that\nhas already been used across five continents. For more information on the\ncompany, its products, and pipeline, visit kurosbio.com\n(https://www.globenewswire.com/Tracker?data=SSCyR1CiAjyhLcNmuQpJHJJs6w8H78BVzAE69ZuSAHvI3zfnsMKrMOmqsadGEyN6jKIivnrCULFuqBa6mMyKmmQAwGhdOQV7WhKjI8fYeruy-jTJZyqGvHavkpzjjX4NxzN_9eHAogDGmM2EEh52TzHmioBhbvcq1PnCyhcTEM7Qk9xbJY1naPc6GJ9XO8wj0O8lCC0Oy9hILGlks473CdRjrljrHsWPb6psyQxVaeHz0on9T6e29mDnDHcdyyveWa4dYOFcF6aWC7gZCp6UKyMabLarpKXhQMiKP3LXgzILqFVYpHE1T_RmxbVaJ_kPrI_XhmvuPZFFAwBvtJ3X3boW_roLB4ZsgGssOZGz1bXO85Lvgfz7Tpt9PAk28iiz).\n\nForward Looking Statements\nThis media release contains certain forward-looking statements that involve\nrisks and uncertainties that could cause actual results to be materially\ndifferent from historical results or from any future results expressed or\nimplied by such forward-looking statements. You are urged to consider\nstatements that include the words “will” or “expect” or the negative\nof those words or other similar words to be uncertain and forward-looking.\nFactors that may cause actual results to differ materially from any future\nresults expressed or implied by any forward-looking statements include\nscientific, business, economic, and financial factors. Against the background\nof these uncertainties, readers should not rely on forward-looking statements.\nThe Company assumes no responsibility for updating forward-looking statements\nor adapting them to future events or developments.\n\n*Adjusted EBITDA excludes research and development costs incurred to complete\nphase 2a of Fibrin-PTH (KUR-113) (discontinued operation), recurring and\none-time share-based compensation, the related social security charges, and\ntemporary tariff-related cost. Management believes this supplemental measures\nprovides useful information to investors by presenting the underlying\noperating performance of the business before the impact of import duties. **19\nof initial 100 patients were active smokers. Radiographic fusion data of the\nsmoker subgroup were not statistically analyzed as a subgroup and were not\nincluded in the peer-reviewed publication of the study.(1) †Results from in\nvivo or in vitro laboratory testing may not be predictive of clinical\nexperience in humans. Please refer to the Instructions for Use for a full list\nof indications, contraindications, precautions, and warnings. MagnetOs is not\ncleared by the FDA or TGA as an osteoinductive bone graft. ‡MagnetOs must\nalso be used with an intervertebral body fusion device cleared by FDA for use\nwith a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA and\nmixed with autograft in posterolateral spine and intervertebral disc space.\nMagnetOs Granules must be hydrated with blood in the intervertebral disc\nspace.\n\n1. Stempels, et al. Spine. 2024;49(19):1323-1331. 2. Van Dijk, LA. 24th SGS\nAnnual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug\n2024. 3. Van Dijk, et al. eCM. 2021;41:756-73. 4. Van Dijk, et al. J Immunol\nRegen Med. 2023;19:100070. 5. Duan, et al. eCM. 2019;37:60-73. 6. Data on\nfile. MagnetOs Putty and MagnetOs Easypack Putty. 7. Instructions for Use\n(IFU) MagnetOs Granules (US). 8. Instructions for Use (IFU) MagnetOs Putty\n(US). 9. Instructions for Use (IFU) MagnetOs Easypack Putty (US). 10.\nInstructions for Use (IFU) MagnetOs MIS (US). 11. Instructions for Use (IFU)\nMagnetOs Flex Matrix (US).\n\nAttachment\n*     Kuros Biosciences Press Release Q3 2026 Results 10-15-26\n(https://ml-eu.globenewswire.com/Resource/Download/a250cd45-25ac-409d-935f-1c858cce8a8b)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ad3777c9-af1f-4b09-a899-3b3d6b8e962d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-15T05:00:00.438773746Z","server_sent_at_ms":1792040400438},"received_at":"2026-10-15T05:00:00.487Z","source_url":null},"analysis":{"id":"157931","press_release_id":"169708","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"earnings","narrative":"Kuros Biosciences reported 9M 2026 medical device sales of USD 141.8 million, up 40% year-over-year, with Group EBITDA up 81% to USD 13.5 million.\n\nThe company raised full-year 2026 guidance to 36-40% sales growth with an adjusted EBITDA margin above 14.5%, and its cash position of USD 19.6 million is ahead of plan.\n\nThe new Alpharetta, Georgia facility began commercial production of MagnetOs, giving Kuros dual-site manufacturing, while its three Level I trials (PROOF 97% enrolled, PRECISE 55%, ASTRA 18%) continue to advance.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Beat-and-raise with 40% sales growth, record EBITDA, and new US manufacturing online — supply resilience plus advancing Level I evidence base."},"keyFigures":{"revenue":"$141.8 million","guidance":"Full-year 2026 sales growth of 36% to 40% and adjusted EBITDA margin of more than 14.5%","revenueYoy":"40%","customDimensions":{"ebitda":"$13.5 million (+81% YoY)","cash_position":"$19.6 million","adjusted_ebitda":"$20.6 million (14.5% margin, +68% YoY)"}},"quotedText":"Our strong performance through the first nine months of 2026 reflects continued revenue growth, record adjusted EBITDA, increasing profitability and a cash position ahead of plan.","namedEntities":{"people":[{"name":"Chris Fair","role":"CEO"},{"name":"Daniel Geiger","role":"CFO"},{"name":"Alexandre Müller","role":"Investor Relations"}],"products":["MagnetOs","MagnetOs Granules","MagnetOs Putty","MagnetOs Easypack Putty","MagnetOs MIS","MagnetOs Flex Matrix","NeedleGrip","Fibrin-PTH (KUR-113)"],"companies":[{"name":"Kuros Biosciences","ticker":"KURN"}],"dollarAmounts":[{"amount":"USD 141.8 million","context":"9M 2026 medical device sales"},{"amount":"USD 13.5 million","context":"9M 2026 Group EBITDA"},{"amount":"USD 20.6 million","context":"9M 2026 adjusted EBITDA"},{"amount":"USD 19.6 million","context":"cash position"}]},"materialImpact":{"score":4,"reasoning":"40% YoY sales growth, 81% EBITDA growth, cash position ahead of plan, and a raised full-year 2026 guidance — a clean beat-and-raise for this medtech issuer."},"tickerRelevance":{"others":[],"primary":"KURN"},"globalImportance":30,"audienceRelevance":20,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"beat-and-raise guidance increase","sectorWeight":"medtech orthobiologics niche","householdBrandBoost":false}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"bullish","material_impact_score":4,"narrative":"Kuros Biosciences reported 9M 2026 medical device sales of USD 141.8 million, up 40% year-over-year, with Group EBITDA up 81% to USD 13.5 million.\n\nThe company raised full-year 2026 guidance to 36-40% sales growth with an adjusted EBITDA margin above 14.5%, and its cash position of USD 19.6 million is ahead of plan.\n\nThe new Alpharetta, Georgia facility began commercial production of MagnetOs, giving Kuros dual-site manufacturing, while its three Level I trials (PROOF 97% enrolled, PRECISE 55%, ASTRA 18%) continue to advance.","key_figures":{"revenue":"$141.8 million","guidance":"Full-year 2026 sales growth of 36% to 40% and adjusted EBITDA margin of more than 14.5%","revenueYoy":"40%","customDimensions":{"ebitda":"$13.5 million (+81% YoY)","cash_position":"$19.6 million","adjusted_ebitda":"$20.6 million (14.5% margin, +68% YoY)"}},"named_entities":{"people":[{"name":"Chris Fair","role":"CEO"},{"name":"Daniel Geiger","role":"CFO"},{"name":"Alexandre Müller","role":"Investor Relations"}],"products":["MagnetOs","MagnetOs Granules","MagnetOs Putty","MagnetOs Easypack Putty","MagnetOs MIS","MagnetOs Flex Matrix","NeedleGrip","Fibrin-PTH (KUR-113)"],"companies":[{"name":"Kuros Biosciences","ticker":"KURN"}],"dollarAmounts":[{"amount":"USD 141.8 million","context":"9M 2026 medical device sales"},{"amount":"USD 13.5 million","context":"9M 2026 Group EBITDA"},{"amount":"USD 20.6 million","context":"9M 2026 adjusted EBITDA"},{"amount":"USD 19.6 million","context":"cash position"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T05:00:06.479Z","global_importance":30,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"beat-and-raise guidance increase","sectorWeight":"medtech orthobiologics niche","householdBrandBoost":false}},"durationMs":5960,"modelName":"glm-5.3-flashx"}}